Samsung Bioepis Considers Listing on Nasdaq to Drive Growth

Samsung Bioepis Co., a developer of biotechnology medicines, is considering going public in the U.S. as its parent companies set their sights on expansion in the lucrative drug industry.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.